Cover Image
市場調查報告書

直腸癌:開發中產品分析

Rectal Cancer - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 229750
出版日期 內容資訊 英文 130 Pages
訂單完成後即時交付
價格
Back to Top
直腸癌:開發中產品分析 Rectal Cancer - Pipeline Review, H1 2017
出版日期: 2017年03月31日 內容資訊: 英文 130 Pages
簡介

直腸癌是結腸(連接大腸跟肛門的部分)下半部產生的腫瘤。直腸癌發病的風險要素包含了年齡和抽煙、結腸癌·直腸癌的家族病史、高脂肪食物或動物主體的飲食,息肉·大腸癌的家族病史等。此外主要會轉移到肝臟及肺臟等組織。一般症狀有排便習慣的變化、下痢、便秘、不完全排便感、血便、頻繁的漲氣、飽脹感、痙攣,原因不明的體重減輕,頻繁的倦怠感·噁心等。主要的治療方法有外科手術及放射線治療、化療,及以上的綜合療法。

本報告提供全球各國治療直腸癌所用的開發中產品開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

直腸癌概要

治療藥的開發

  • 直腸癌開發中產品:概要

各企業開發中的直腸癌治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

直腸癌治療藥:開發中的產品一覽(各企業)

直腸癌治療藥的開發企業

  • AbbVie Inc
  • Advaxis, Inc.
  • Cerulean Pharma, Inc.
  • Hanwha Chemical Corporation
  • Karyopharm Therapeutics, Inc.
  • Regeneron Pharmaceuticals Inc
  • Taiwan Liposome Company, Ltd.

直腸癌:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

直腸癌治療藥:開發暫停的產品

直腸癌相關產品的開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9099IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rectal Cancer - Pipeline Review, H1 2017, provides an overview of the Rectal Cancer (Oncology) pipeline landscape.

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as the liver and the lungs. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting. Rectal cancer treatment includes surgery, radiation therapy or chemotherapy, or a combination of these approaches

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rectal Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 5, 5 and 1 respectively.

Rectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rectal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Rectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rectal Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rectal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rectal Cancer - Overview
    • Rectal Cancer - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Rectal Cancer - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Rectal Cancer - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Advaxis Inc
    • Cerulean Pharma Inc
    • GlaxoSmithKline Plc
    • Karyopharm Therapeutics Inc
    • Peregrine Pharmaceuticals Inc
    • Regeneron Pharmaceuticals Inc
    • Taiwan Liposome Company Ltd
    • Targovax ASA
  • Rectal Cancer - Drug Profiles
    • axalimogene filolisbac - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bavituximab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CRLX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ganetespib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2256098 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NM-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONCOS-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • selinexor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TLC-388 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • veliparib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ziv-aflibercept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Rectal Cancer - Dormant Projects
  • Rectal Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Apr 23, 2014: Abbvie To Present Data On Veliparib At The 2014 American Society Of Clinical Oncology Annual Meeting
      • Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Rectal Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Rectal Cancer - Pipeline by AbbVie Inc, H1 2017
  • Rectal Cancer - Pipeline by Advaxis Inc, H1 2017
  • Rectal Cancer - Pipeline by Cerulean Pharma Inc, H1 2017
  • Rectal Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Rectal Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Rectal Cancer - Pipeline by Peregrine Pharmaceuticals Inc, H1 2017
  • Rectal Cancer - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
  • Rectal Cancer - Pipeline by Taiwan Liposome Company Ltd, H1 2017
  • Rectal Cancer - Pipeline by Targovax ASA, H1 2017
  • Rectal Cancer - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Rectal Cancer, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top